Neurokinin B Antibody Blocking Peptide
Novus Biologicals, part of Bio-Techne | Catalog # NB300-201PEP
Key Product Details
Conjugate
Unconjugated
Applications
Antibody Competition, Block/Neutralize, Immunohistochemistry
Product Specifications
Description
A TAC3 antibody blocking peptide.
Applications
Block/Neutralize (Check Peptide apps. Use reported in scientific literature (PMID 20038444))
Immunohistochemistry-Frozen (reported in scientific literature (PMID 24735328))
Immunohistochemistry-Frozen (reported in scientific literature (PMID 24735328))
Application Notes
This peptide is useful as a blocking peptide for NB300-201. For further blocking peptide related protocol, click here.
Specificity
This peptide is specific for NB300-201 only.
Protein / Peptide Type
Antibody Blocking Peptide
Formulation, Preparation and Storage
NB300-201PEP
Formulation | Peptide dissolved in dH2O. Contains no BSA. |
Preservative | No Preservative |
Concentration | 1.0 mg/ml |
Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Store at -80C. Avoid freeze-thaw cycles. |
Background: Neurokinin B
Three tachykinin receptor types have been characterized, NK-1, NK-2 and NK-3 which have preferential affinities for SP, NKA and NKB respectively. All three receptors share a high degree of sequence homology, have seven transmembrane spanning domains and similar signal transduction mechanisms (e.g. G-protein coupled activation of phospholipase C).
Alternate Names
gamma tachykinin 3, neurokinin beta, neurokinin B-like, neuromedin K, preprotachykinin B, PRO1155, tachykinin 3, tachykinin-3, ZNEUROK1NKNBNKB
Gene Symbol
TAC3
Additional Neurokinin B Products
Product Documents for Neurokinin B Antibody Blocking Peptide
Product Specific Notices for Neurokinin B Antibody Blocking Peptide
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...